About this trial
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Eligibility criteria
Qualifiers
had preeclampsia in the past 5 years,
18 years or older
Disqualifiers
current daily aspirin use,
skin diseases,
current tobacco or nicotine use (including vaping),
diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR < 60 mL/min/1.73m2,
Trial design
Treatments tested in this trial
- Aspirin
- Placebo
Treatment groups
Sponsors and collaborators
Anna Stanhewicz, PhD
Lead sponsor
University of Iowa
Sponsor institution